Elevated levels of IL-6, NLR, or both, resulted in an increased hazard for a shorter progression-free and shorter overall survival relative to the IL-6low/NLRlow group in NSCLC patients (Fig 5). Here, IL6 is linked to non-small cell lung carcinoma.